CAR T-Cell Therapy Opportunity within Diffuse Large B-Cell Lymphoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
CAR T-cell therapy represents a promising breakthrough in treating Diffuse Large B-cell Lymphoma (DLBCL) patients. This malignancy has historically posed challenges in achieving long-term remission. Typically, patients with DLBCL respond to initial chemotherapy containing anthracycline and rituximab with an overall response rate of approximately 60%. However, the long-term event-free survival rate is only 50%, indicating a significant relapse or treatment failure risk. Unfortunately, for a substantial portion of patients, approximately 30% to 40%, relapse occurs despite receiving intensive salvage chemotherapy that may incorporate monoclonal antibodies such as rituximab or ofatumumab, as well as autologous stem cell transplantation (ASCT). The outcomes are frequently unfavorable in these cases, with an overall response rate ranging from 27% to 63% and long-term survival rates reaching up to 48%. Additionally, a significant challenge arises in only 50% of relapsed patients being eligible for ASCT due to inadequate responses to salvage chemotherapy or issues with stem cell collection. However, the advent of CAR T-cell therapy brings newfound hope for patients with multiply relapsed DLBCL, a population for whom durable remission and cure were previously improbable. CAR T-cell therapy involves genetically modifying a patient's T cells to recognize and target cancer cells more effectively, bolstering the immune system's ability to fight the lymphoma. Given its remarkable potential, CAR T-cell therapy is now emerging as a compelling second-line treatment option for suitable patients with refractory or early relapsing DLBCL. The therapy's ability to achieve durable remission and even potential cures makes it a promising candidate for becoming the new standard of care in this setting.
Thelansis’s “CAR T-Cell Therapy Opportunity within Diffuse Large B-Cell Lymphoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential CAR T-Cell Therapy Opportunity within Diffuse Large B-Cell Lymphoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of CAR T-Cell Therapy Opportunity within Diffuse Large B-Cell Lymphoma across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
CAR T-Cell Therapy Opportunity within Diffuse Large B-Cell Lymphoma Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment